Lexeo Therapeutics, Inc. (LXEO)

Market Cap	402.03M +172.1%
Revenue (ttm)	n/a
Net Income	-87.50M
EPS	-1.33
Shares Out	78.52M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,834,966
Open	4.48
Previous Close	4.48
Day's Range	4.48 - 5.20
52-Week Range	2.51 - 10.99
Beta	1.53
Analysts	Strong Buy
Price Target	19.64 (+283.59%)
Earnings Date	May 11, 2026

About LXEO

Lexeo Therapeutics, Inc., a clinical stage genetic medicine company, focuses on hereditary and acquired diseases with high unmet need in the United States. Its product pipeline comprises LX2006, an AAVrh10-based gene therapy candidate, which is in phase 1/2 clinical trial to treat friedreich ataxia cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate, which is in phase 1/2 to deliver a functional plakophilin-2 (PKP2) gene to cardiac muscle for the treatment of PKP2-ACM; and LX2021, a gene therapy candidate, which is in preclinical tr...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Nov 3, 2023
• Employees: 59
• Stock Exchange: NASDAQ
• Ticker Symbol: LXEO
• Website: https://www.lexeotx.com

Analyst Summary

According to 11 analysts, the average rating for LXEO stock is "Strong Buy." The 12-month stock price target is $19.64, which is an increase of 283.59% from the latest price.

Price Target

$19.64

(283.59% upside)

Analyst Consensus: Strong Buy